Connect your AI

Cogent Biosciences, Inc. COGT Price / book

Price / book at other companies

PfizerPFE

1.8×+0.2×

AmgenAMGN

20.6×-6.3×

IncyteINCY

3.3×+0.1×

Tango TherapeuticsTNGX

7.6×+6.7×

CG OncologyCGON

5.2×+2.6×

Scholar RockSRRK

20.5×+10.7×

Other financials

Income statement

Operating income-$103.6M-38.3%

Net income-$97.4M-35.2%

EPS (diluted)-$0.53-1.9%

Balance sheet

Cash & equivalents$241.2M+91.4%

Total debt$15.5M-9.4%

Total equity$607.7M+177%

Total assets$903.0M+218%

Cash flow

Operating cash flow-$86.9M-30.6%

CapEx$449.0K-17.9%

Free cash flow-$87.3M-30.2%

Valuation

Market cap$5.9B+816%

Enterprise value$5.68B+951%

P/S749.8×—

Profitability

Operating margin-1,044.3%—

Net margin-950.4%—

FCF margin-184.7%—

Returns & leverage

Return on equity-85.7%+1.7pp

Debt / equity0×-0.1×

Current ratio15.1×+10.0×

Where this comes from

Calculated from Cogent Biosciences, Inc.’s reported figures.

market cap/total stockholders equity=10.3×

Based on the most recent quarter.

The official record: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cogent Biosciences, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Cogent Biosciences, Inc.'s price / book?: Cogent Biosciences, Inc. (COGT) reported price / book of 10.3× in Q1 2026.
How has Cogent Biosciences, Inc.'s price / book changed year-over-year?: Cogent Biosciences, Inc.'s price / book increased by 230.1% year-over-year, from 3.1× to 10.3×.
What is the long-term trend for Cogent Biosciences, Inc.'s price / book?: Over 5 years (2020 to 2025), Cogent Biosciences, Inc.'s price / book has grown at a 35.1% compound annual growth rate (CAGR), from 1.9× to 8.6×.
What does price / book mean?: Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.